Re: Abiraterone Acetate and Prednisolone With or Without Enzalutamide for High-risk Non-metastatic Prostate Cancer: A Meta-analysis of Primary Results from Two Randomized Controlled Phase 3 Trials of the STAMPEDE Platform Protocol

Eur Urol. 2022 Jun;81(6):621. doi: 10.1016/j.eururo.2022.02.011. Epub 2022 Feb 19.

Authors

Viktor Grünwald¹, Carsten-Henning Ohlmann², Boris Hadaschik³

Affiliations

¹ Interdisciplinary Genitourinary Oncology, Department of Urology and Department of Medical Oncology, University Hospital Essen, Essen, Germany.
² Department of Urology, Johanniter Hospital Bonn, Bonn, Germany.
³ Department of Urology, University Hospital Essen, Essen, Germany. Electronic address: boris.hadaschik@uk-essen.de.

PMID: 35193775
DOI: 10.1016/j.eururo.2022.02.011

No abstract available

MeSH terms

Abiraterone Acetate / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Benzamides
Clinical Trials, Phase III as Topic
Humans
Male
Meta-Analysis as Topic
Nitriles / therapeutic use
Phenylthiohydantoin / therapeutic use
Prednisolone / therapeutic use
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / pathology
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / pathology
Randomized Controlled Trials as Topic
Treatment Outcome

Substances

Abiraterone Acetate
Benzamides
enzalutamide
Nitriles
Phenylthiohydantoin
Prednisolone